Study aim: Determination the effect of resveratrol supplementation on some oxidative stress and inflammatory biomarkers, fatigue scale, fasting blood sugar and lipid profile in patients with Multiple Sclerosis. Design: A clinical trial with control group including a sample size of 60 people, with parallel group, double-blind, randomized Settings and conduct: Referred to the Khouzestan MS Association in 2023, selection of 60 patients based on inclusion and exclusion criteria, randomization into intervention and control groups. Blinding of patients and researchers, coding by a third party who does not know the details. Participants/Inclusion and exclusion criteria: The disease is diagnosed according to McDonald's criteria. EDSS score 0 to 5 The clinical condition of the patient is relapse-remittance. Age 18 to 65 years The patient consumes alcohol, tobacco or drugs. Use of antioxidant supplements and hormonal treatments. Body mass index(BMI) higher than 30. Any progressive or autoimmune diseases. Intervention groups: Study groups include resveratrol and placebo consumer groups Main outcome variables: MDAT, TNF-α, Fasting blood sugar, Lipid profile, Fatigue Scale